We are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. We developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.  We believe the novel coronavirus, or COVID-19, pandemic has shown the infectious disease testing infrastructure in the United States was not designed to accommodate the immediate demands of infectious disease control on a mass-population scale. The testing options today are too expensive, inaccurate, or are inaccessible due to slow time to results or complexity. Our LUCIRA COVID-19 All-In-One Test Kit, or our COVID-19 test kit, is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. Our initial focus is within respiratory diseases, starting with COVID-19 and influenza A and B virus indications.

On Nov. 17, 2020, we received an Emergency Use Authorization from the FDA for (1) prescription at-home use with self-collected nasal swab specimens in individuals aged 14 and older who are suspected of COVID-19 by their healthcare provider and (2) use at the point-of-care with self-collected nasal swab specimens in individuals aged 14 and older, and in individuals aged 13 and under when the specimen is collected by a healthcare provider at the point of care.

(Note: Lucira Health upsized its IPO at pricing on Feb. 4, 2021: 9 million shares at $17 – up from 7.81 million shares at $15 to $17 in the prospectus – to raise $153 million; this IPO was priced at the top of its range.)